Copyright
©The Author(s) 2025.
World J Psychiatry. Jan 19, 2025; 15(1): 98737
Published online Jan 19, 2025. doi: 10.5498/wjp.v15.i1.98737
Published online Jan 19, 2025. doi: 10.5498/wjp.v15.i1.98737
Table 1 Comparison of baseline data between the two groups
| Group | Sex (female/male) | Age (years) | Tumor type, n (%) | |||
| Bladder cancer | Prostate cancer | Kidney cancer | Ureter cancer | |||
| Conventional group (n= 55) | 20/35 | 45.67 ± 6.51 | 28 (50.91) | 8 (14.55) | 15 (27.27) | 4 (7.27) |
| Joint intervention group (n= 55) | 19/36 | 47.05 ± 5.92 | 29 (52.73) | 9 (16.36) | 12 (21.82) | 5 (9.09) |
| χ2/t | 0.040 | -1.165 | 0.521 | |||
| P value | 0.842 | 0.247 | 0.914 | |||
- Citation: Liu J, Guo YP, Lu YM, Wang BL. Clinical value of combining epirubicin with mindfulness intervention in patients with urinary system tumors and depression. World J Psychiatry 2025; 15(1): 98737
- URL: https://www.wjgnet.com/2220-3206/full/v15/i1/98737.htm
- DOI: https://dx.doi.org/10.5498/wjp.v15.i1.98737